Chesterbrook

Researchers are investigating embryos classified as "complex aneuploid" (having three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) using preimplantation genetic testing for aneuploidy (PGT-A). The study aims to find out if embryos initially labeled with multiple chromosomal abnormalities might actually have normal chromosomal makeup when re-tested, allowing for possible transfer and the chance to achieve a live birth. This research responds to recent findings suggesting some embryos classified as chaotic can result in healthy pregnancies, challenging past assumptions about their viability. The study involves re-biopsy and genetic reanalysis of embryos previously identified as complex aneuploid or chaotic through next-generation sequencing (NGS) based PGT-A. Patients with embryos meeting these criteria are enrolled prospectively, and embryos are stored for research. An independent geneticist will review the re-biopsy results to confirm findings. This portion of the study focuses only on consent for re-biopsy and reanalysis, not on decisions regarding embryo transfer. Participants contribute embryos for re-biopsy, and researchers analyze the reproducibility of the initial PGT-A results over one year. The study tracks whether re-biopsy reveals euploid (normal chromosomal) embryos among those initially called complex or chaotic. Data collected will help understand the accuracy of initial testing and the potential to reduce embryo wastage. Participation is voluntary, and decisions will not impact current or future patient care.